Meeting
2023 ASCO Annual Meeting
Clonal hematopoiesis (CH) associated mutations in patients with advanced solid tumors enrolled in phase I clinical trials.
Authors
Julieta Rodriguez
Drug Development Department, Gustave Roussy Cancer Campus, Villejuif, France
Julieta Rodriguez , Arnaud Bayle , Arnaud Pages , Francois-Xavier Danlos , Damien Vasseur , Etienne Rouleau , Ludovic Lacroix , Beatriz Alonso de Castro , Vincent Goldschmidt , Lauren Seknazi , Antoine Hollebecque , Jean-Marie Michot , Stephane Champiat , Aurelien Marabelle , Kaissa Ouali , Christophe Marzac , Santiago Ponce Aix , Antoine Italiano , Jean Baptiste Micol , Capucine Baldini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3056)
DOI
10.1200/JCO.2023.41.16_suppl.3056
Abstract #
3056
Poster Bd #
254
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Prevalence of inferred clonal hematopoiesis (CH) detected on comprehensive genomic profiling (CGP) of solid tumor tissue or circulating tumor DNA (ctDNA).
First Author: Emmanuel S. Antonarakis
Poster
2020 ASCO Virtual Scientific Program
Clonal hematopoiesis in the bone marrow and blood of healthy volunteers.
First Author: Pierre Hirsch
Poster
2018 ASCO Annual Meeting
Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired commercial next-generation sequencing assays.
First Author: Catherine Callaghan Coombs
Poster
2023 ASCO Annual Meeting
Outcomes of individuals with clonal hematopoiesis evaluated at a cancer center.
First Author: Kelly Sharon Chien